Feedback
Settings

Settings

Goto Application

7,521 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(GFYLSDSUCHVORB-IOSLPCCCSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 753
1.WO/2026/088246METHOD FOR PRODUCING LOW-MOLECULAR-WEIGHT COMPOUND
WO - 30.04.2026
Int.Class C12P 13/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
13Preparation of nitrogen-containing organic compounds
04Alpha- or beta-amino acids
22Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
 Appl.No PCT/JP2024/037332 Applicant NTT, INC. Inventor TAKEBE Hiroaki
Provided is a method for producing a low-molecular-weight compound, the method involving isolating the low-molecular-weight compound contained in a culture supernatant of algae.
2.WO/2026/085440SERIAL VACCINATIONS USING MANNAN ADJUVANTS
WO - 23.04.2026
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
 Appl.No PCT/US2025/051470 Applicant THE CHILDREN'S MEDICAL CENTER CORPORATION Inventor KARP, Jeffrey M.
Provided herein are serial vaccination methods to induce an immune response against a pathogen (e.g., Beta coronavirus) comprising administering a first composition comprising a nucleic acid encoding a first antigen (e.g., a first Beta coronavirus antigen) and administering a second composition comprising a nucleic acid encoding an second antigen (e.g., a second Beta coronavirus antigen), and wherein the first composition and/or the second composition comprises an adjuvantation system comprising a mannan (e.g., a plant mannan or a fungal mannan).
3.WO/2026/081470RNA POLYMERASE VARIANT AND USE THEREOF
WO - 23.04.2026
Int.Class C12N 9/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
10Transferases (2.)
12transferring phosphorus containing groups, e.g. kinases (2.7)
 Appl.No PCT/CN2025/094736 Applicant NANJING VAZYME BIOTECH CO., LTD. Inventor JIN, Qiuheng
Provided are a T7RNA polymerase variant and use thereof. The amino acid sequence of the T7RNA polymerase variant, relative to SEQ ID NO: 1, comprises at least one substitution or deletion selected from the following amino acid sites: R34, K172, Y178, R386, D388, Q435, N437, and D438. The variant, relative to a wild-type T7RNA polymerase, has improved catalytic activity, and can improve the capping rate of mRNA products during in vitro transcription. In addition, a method for preparing RNA using the variant is also provided. Using the method to prepare RNA molecules, more capped mRNAs can be obtained.
4.WO/2026/082097POLYPEPTIDE, RNA MOLECULE AND MEDICAL USE THEREOF
WO - 23.04.2026
Int.Class C07K 14/515
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
515Angiogenic factor; Angiogenin
 Appl.No PCT/CN2025/128012 Applicant SHANGHAI REGENELEAD THERAPIES CO., LTD. Inventor ZHANG, Jiao
The present disclosure relates to a polypeptide, an RNA molecule and a medical use thereof, and specifically relates to an ANGPTL polypeptide, an RNA molecule, a polynucleotide, a vector, lipid nanoparticles, a pharmaceutical composition and a medical use thereof.
5.WO/2026/085428IONIZABLE AMPHIPHILIC JANUS DENDRIMERS, DELIVERY SYSTEMS COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO - 23.04.2026
Int.Class A61K 39/385
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
385Haptens or antigens, bound to carriers
 Appl.No PCT/US2025/051447 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor PERCEC, Virgil
The invention relates to ionizable amphiphilic Janus dendrimers with different linker lengths. In some embodiments, the different linkers enable delivery of the agent to a specific target of interest (e.g., kidney, heart, lung, liver, lymph nodes, spleen, or any combination thereof). In some embodiments, the invention relates to nanoparticles comprising said ionizable amphiphilic Janus dendrimers. In some embodiments, the invention relates to compositions comprising said ionizable amphiphilic Janus dendrimers. In some aspects, the present invention also relates to methods of inducing an adaptive immune response in a subject comprising administering to the subject an effective amount of said nanoparticle or said composition.
6.WO/2026/085452OPTIMIZED FORMULATION OF IONIZABLE AMPHIPHILIC JANUS DENDRIMER DELIVERY SYSTEMS, AND METHODS OF USE THEREOF
WO - 23.04.2026
Int.Class C07D 295/15
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
295Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
04with substituted hydrocarbon radicals attached to ring nitrogen atoms
14substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
145with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
15to an acyclic saturated chain
 Appl.No PCT/US2025/051492 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor ATOCHINA-VASSERMAN, Elena
Nanoparticles comprising at least one amphiphilic Janus dendrimer are described as well as methods of delivering an agent to a target of interest (e.g., lung, liver, lymph nodes, and spleen) using said nanoparticle and methods of inducing an adaptive immune response in a subject comprising administering to the subject an effective amount of a composition comprising at least one nucleoside-modified RNA encoding at least one antigen and at least one amphiphilic Janus dendrimer.
7.WO/2026/085437LYME DISEASE VACCINE AND METHOD OF USE THEREOF
WO - 23.04.2026
Int.Class A61K 39/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
 Appl.No PCT/US2025/051464 Applicant HEALTH RESEARCH, INC. Inventor LIN, Yi-Pin
Provided is an immunogenic composition for use in raising immunity against the agent of Lyme disease. The composition is based on variants of CspZ and comprises a polypeptide of SEQ ID NO: 1, except that (a) the amino acid whose position corresponds to amino acid 188 of SEQ ID NO: 1 is any amino acid other than tyrosine; and the amino acid whose position corresponds to amino acid 192 of SEQ ID NO: 1 is any amino acid other than tyrosine; and (b) one or both of the amino acids acid whose position corresponds to amino acid 164 of SEQ ID NO: 1 may be an amino acid other than inosine and an amino acid whose position corresponds to amino acid 168 of SEQ ID NO: 1 may be an amino acid other than cysteine. Also provided is a polynucleotide encoding any of the foregoing polypeptides and a method of vaccinating against Lyme disease comprising administering the polypeptide or RNA encoding the polypeptide to a subject.
8.WO/2026/085498ENGINEERED CRISPR ASSOCIATED PROTEINS
WO - 23.04.2026
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/US2025/051561 Applicant ORTHOBIO THERAPEUTICS, INC. Inventor GENTSCH, George
The present disclosure provides compositions and methods for enhancing gene editing. In some aspects, the compositions and methods are used prevent the progression or treat diseases such as osteoarthritis and other joint disorders that are characterized by an inflammatory component.
9.WO/2026/082154ANTI-BETA AMYLOID ANTIBODIES AND USES THEREOF
WO - 23.04.2026
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
 Appl.No PCT/CN2025/128337 Applicant LEPU BIOPHARMA CO., LTD. Inventor LIU, Fang
Deposition of N-terminally truncated and pyroglutamate-modified Abeta peptides (AβpE3) play an important role in the aggregation of the amyloid-β (Aβ) protein in the brain. The N-terminally truncated and pyroglutamate-modified Abeta peptides, therefore, can be a suitable target for the prevention and treatment of Alzheimer's Disease (AD). Disclosed herein are antibodies and fragments having excellent specificity to N-terminally truncated and pyroglutamate-modified Abeta peptides, as well as uses of these antibodies and fragments for the prevention and treatment of AD.
10.WO/2026/080612COMPOSITIONS AND METHODS FOR SMALL CIRCULAR RNA-BASED IMMUNOTHERAPIES
WO - 16.04.2026
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No PCT/US2025/050083 Applicant VIRGINIA COMMONWEALTH UNIVERSITY Inventor ZHU, Guizhi
Provided herein are compositions and methods for inducing an immune response using small circular ribonucleic acid (circRNA) molecules. In particular, the compositions comprise a small circRNA encoding at least one antigen or immunogenic peptide fragment, wherein the composition is self-adjuvanted and configured to elicit a T-cell–mediated immune response.
# -